Cornerstone (康诺思腾), a Chinese surgical robot company, recently announced the completion of a new round of CNY 800 million in financing.
Cornerstone is a high-tech innovation company established in 2019, with a founding team composed of the world's top medical and surgical robot experts. Cornerstone is committed to the research and development of innovative surgical robots, and focuses on the global market, aiming to create a safe and efficient surgical robot platform. At present, the company has completed the multi-line layout of soft tissue surgical robots and other major specialty surgical robots.
Cornerstone has taken an important step in 2022, and its first-generation porous endoscopic surgical robot products have officially entered the human clinical stage. This marks that Cornerstone has become the first innovative surgical robot company in China to face the world and realize clinical trials in the international market.
The global surgical robot market is expected to reach USD 28.51 billion in 2025, with a compound annual growth rate of 27.1% (from 2021 to 2025). It is estimated that by 2030, the size of the global surgical robot market will increase to USD 61.90 billion. This trend shows that with the rapid development of minimally invasive surgical techniques, the surgical robotics market has great growth potential.
Ou Guowei (欧国威), the founder of Cornerstone, previously introduced that the company has set up a global organizational distribution since its inception. It has branches in Shenzhen, Hong Kong, Beijing, and the United States. It has established three major R&D centers and built a mass production factory.
Surgical robots have attracted a lot of companies. Representative companies in China include TINAVI (天智航), WEGO (威高), MicroPort (微创), and Broncus (堃博医疗); internationally, Intuitive Surgical, Medtronic, and Stryker in the United States, Titan Medical in Canada, Momentus Surgical in Israel, Moon Surgical in France are quite powerful.
In this round of financing, Cornerstone introduced BridgeOne Technology Investment (道合科技投资) and LCIG (联想创投) and received additional investment from old shareholders TSING SONG CAPITAL (清松资本), LONG-Z (美团龙珠), Qiming Venture Partners (启明创投), Lilly AsiaVentures (礼来亚洲基金), New World Development (新世界发展集团) and K2VC (险峰). This round of financing will promote the company to accelerate the development of new products of surgical robots, clinical trials, registration and listing, and global promotion.